	US 12,201,682 B2
	Henipavirus vaccine
Edith Jasny, Stuttgart (DE); and Benjamin Petsch, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Nov. 3, 2022, as Appl. No. 18/052,541.
Application 18/052,541 is a division of application No. 16/471,541, granted, now 11,524,066, previously published as PCT/EP2017/084525, filed on Dec. 22, 2017.
Claims priority of application No. PCT/EP2016/082672 (WO), filed on Dec. 23, 2016.
Prior Publication US 2023/0226167 A1, Jul. 20, 2023
Int. Cl. C12N 7/00 (2006.01); A61K 39/145 (2006.01); A61K 39/155 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/155 (2013.01) [C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6093 (2013.01); A61K 2039/622 (2013.01); A61K 2039/70 (2013.01); C12N 2760/18222 (2013.01); C12N 2760/18234 (2013.01); C12N 2760/18271 (2013.01)]

21 Claims

1. A RNA molecule comprising at least one coding sequence encoding at least one antigenic protein derived from a Nipah virus glycoprotein and at least one coding sequence encoding at least one antigenic protein derived from Nipah virus fusion protein, wherein the at least one antigenic protein derived from the Nipah virus glycoprotein is at least 90% identical to SEQ ID NO: 584; and wherein the at least one antigenic protein derived from Nipah virus fusion protein is at least 90% identical to SEQ ID NO: 573.